Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Heron Therapeutics (HRTX) over the last 10 years, with Q3 2025 value amounting to $12.4 million.

  • Heron Therapeutics' Short-term Investments fell 7249.33% to $12.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.4 million, marking a year-over-year decrease of 7249.33%. This contributed to the annual value of $33.5 million for FY2024, which is 3527.99% down from last year.
  • According to the latest figures from Q3 2025, Heron Therapeutics' Short-term Investments is $12.4 million, which was down 7249.33% from $24.1 million recorded in Q2 2025.
  • Heron Therapeutics' 5-year Short-term Investments high stood at $106.7 million for Q1 2021, and its period low was $12.4 million during Q3 2025.
  • Its 5-year average for Short-term Investments is $47.8 million, with a median of $45.1 million in 2024.
  • Its Short-term Investments has fluctuated over the past 5 years, first crashed by 7346.71% in 2021, then surged by 14750.28% in 2024.
  • Over the past 5 years, Heron Therapeutics' Short-term Investments (Quarter) stood at $67.0 million in 2021, then increased by 3.65% to $69.5 million in 2022, then decreased by 25.55% to $51.7 million in 2023, then crashed by 35.28% to $33.5 million in 2024, then plummeted by 62.91% to $12.4 million in 2025.
  • Its last three reported values are $12.4 million in Q3 2025, $24.1 million for Q2 2025, and $31.4 million during Q1 2025.